2.98 USD
▲-0.11+6.05%
盘后 2.88 +2.49%
2026-08-03
市值
$538.24M
市盈率
—
EPS
-1.24
股息率
—
52 周区间
2.67 – 6.94
成交量
3.16M
Beta
2.27
目标价
7.12
52W 低 2.6752W 高 6.94
价格走势
公司简介
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in...